Company: SCLXW
Filing Date: 2025-08-04
Form Type: S-1
Source: 0001193125-25-172703
Chunk: 486

Company: Scilex Holding Co
Filing Date: 2025-08-04
Form: S-1
Chunk 486
---
LYXYB in the U.S. As of December 31, 2024 and 2023, the Company had ending balances of accrued royalty payables of $ 0.1million and $ 5.0thousand, respectively, which was recorded as accrued expenses under current liabilities on F-20

the consolidated balance sheets. During the years ended December 31, 2024 and 2023, the Company made royalty payments in the amount of $ 0.3million and $ 26.0thousand, respectively. As of December 31, 2024, nosales or regulatory milestone payments had been accrued as there were no potential milestones yet considered probable of achievement.

4. Fair Value Measurements

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis and the level of inputs used in such measurements (in thousands):

|                                          |     | December 31, 2024 |        |     |                                        |   |     |                                            |   |     |                                         |        |
|:-----------------------------------------|:----|:------------------|-------:|:----|:---------------------------------------|:--|:----|:-------------------------------------------|:--|:----|:----------------------------------------|-------:|
|                                          |     | Balance           |        |     | Quoted Pricesin ActiveMarkets(Level 1) |   |     | SignificantOtherObservableInputs (Level 2) |   |     | SignificantUnobservableInputs (Level 3) |        |
| Liabilities                              |     |                   |        |     |                                        |   |     |                                            |   |     |                                         |        |
| Oramed Note                              |     | $                 | 12,161 |     | $                                      | — |     | $                                          | — |     | $                                       | 12,161 |
| Tranche B Notes                          |     |                   | 23,560 |     |                                        | — |     |                                            | — |     |                                         | 23,560 |
| Purchased Revenue Liability              |     |                   |  6,800 |     |                                        | — |     |                                            | — |     |                                         |  6,800 |
| Derivative liabilities                   |     |                   | 18,303 |     |                                        | — |     |                                            | — |     |                                         | 18,303 |
| Other long-term liabilities              |     |                   |    155 |